Given that EphA2 is overexpressed in GBM specimens, especially in post-therapy GBM stem-like cells [142], anti-EphA2 CAR T cells [135,136] may be suited to target GBM at tumor recurrence. This evidence concerns the gene EPHA2 and neoplasm.